SEC EDGARJUN 241 min read$INSM

Smith Michael Alexander sold $173K of INSM

Smith Michael Alexander (Chief Legal Officer) sold 1,806 shares of INSMED Inc (INSM) at $95.82 ($0.17M total) on 2026-06-22 under a Rule 10b5-1 trading plan.

Original reporting

SEC EDGAR · Smith Michael Alexander

Published Jun 24, 2026, 4:00 PM UTC

Analysis

AlphAI AI DeskAI-generated

Added to AlphAI Aug 6, 2026, 6:51 AM UTC. Informational, not investment advice.

How this was made

AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About AlphAI AI Desk Scoring methodology Report an issue

AlphAI market briefInsider activity

Primary signal

$INSM

Neutral

medium confidence

Mentioned

$INSM

Relevance

3/10

AlphAI data visualization · based on SEC EDGAR

Decision brief

The 30-second read

$INSMNeutralLow

Why it matters

The disclosure confirms an officer-level open-market sale of $173,050.92 worth of INSM shares, executed under a pre-arranged 10b5-1 plan.

Market read

This is a routine insider sale filing with limited incremental information for trading decisions.

What to watch

Traders may over-weight single insider sales; the more informative signal would be repeated sales across multiple insiders or changes in plan parameters, which are not provided here.

Relevance 3/10Novelty 3/10Timing: filed 2026-06-24, sale dated 2026-06-22

Background

The article is an SEC Form 4 insider transaction disclosure for INSMED Inc.

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$INSMNeutralMedium confidence

Context

INSMED Form 4 shows Chief Legal Officer Michael Alexander sold 1,806 shares at $95.82 under a 10b5-1 plan.

Expected impact

Likely minimal, short-lived impact unless follow-on selling accelerates.

Evidence & confidence

The filing is a scheduled open-market sale under a pre-arranged 10b5-1 plan, which typically reduces interpretive value versus discretionary sales.

Market effects

Sector

No sector-level implications; this is company-specific insider transaction disclosure.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Because it is a 10b5-1 plan, the sale may reflect liquidity/compensation mechanics rather than bearish expectations.

Key entities

issuer
INSMED Inc
Company whose insider transaction is disclosed on Form 4.
insider
Michael Alexander Smith
Chief Legal Officer who sold shares.

Read at source ← All news

OCT 22

$INSMMed

Brensocatib Launches in Japan for Non-CF Bronchiectasis

Insmed Inc. launched Brinsupri (brensocatib hydrate) in Japan for non-cystic fibrosis bronchiectasis, following approvals in the U.S. and Europe. The treatment, backed by clinical trial data, is the first of its kind in Japan. Insmed executives highlighted its potential to address unmet medical needs and improve patient outcomes.

ajmc.com3 min

OCT 20

$INSMLow

Insmed Appoints Former Sanofi CEO Paul Hudson and Utpal Koppikar to Board

Insmed Inc. (INSM) added former Sanofi CEO Paul Hudson and Verily Health CFO Utpal Koppikar to its board, enhancing commercial and financial expertise. The company is expanding globally and advancing its drug pipeline. Hudson and Koppikar bring extensive experience in pharmaceutical operations and financial management, respectively.

citybiz.co2 min

OCT 19

$INSMHigh

Insmed launches bronchiectasis treatment in Japan

Insmed Incorporated (INSM) launched BRINSUPRI Tablets 25 mg in Japan for treating non-cystic fibrosis bronchiectasis in adults and pediatric patients 12+. The therapy, approved in August 2026, is the first of its kind in Japan. BRINSUPRI is also approved in the U.S. and EU for similar indications. Common side effects include rash, dry skin, and hypertension. Insmed is a biopharmaceutical company based in New Jersey.

investing.com1 min

OCT 19

$INSMMed

In Japan, patients can now get the only approved treatment for a lung disease that permanently widens airways.

Insmed Inc. announced that BRINSUPRI, the first approved treatment for non-cystic fibrosis bronchiectasis (NCFB), is now available by prescription in Japan. BRINSUPRI is a once-daily oral therapy designed to reduce airway inflammation. The company highlighted the substantial disease burden of NCFB and the need for effective treatments. Insmed also provided details on the drug's safety profile and potential side effects, including dermatologic and gingival adverse reactions.

stocktitan.net2 min

OCT 15

$INSMMedAI 8/10

Insmed launches four phase 3 trials for lung disease therapy

Insmed Inc. (INSM) launched four Phase 3 trials for its lung disease therapy, treprostinil palmitil. The PALM program includes studies for pulmonary arterial hypertension, pulmonary hypertension with interstitial lung disease, progressive pulmonary fibrosis, and idiopathic pulmonary fibrosis. Three trials have started, with the fourth expected in early 2027. The therapy is not yet approved.

investing.com2 min

OCT 14